Fantastic post Stonemasonn. Thank you for this little bit of detective work. The brochure is very well done. It's exciting to be adding 3 additional revenue streams in short order with VascuCel, CardioCel Neo (The one) and CardioCel Curve (Aortic Repair Patch).
As WP clearly stated these are all new and additional revenue streams none of which were in our revenue guidance of > 21 million. So it is easy to see how that revenue projection has already increased from code red to the AGM by a whopping 30% although not really explicitly announced. However, the projections are there for all to see.
So imagine if we can eek out just 1 more additional million dollars. That would put a nice number in the FY 17 report of 100% revenue growth for the year. I am sure this is one of Wayne's "internal" targets and one I am confident AHZ can achieve. Exciting times to be an Admedus shareholder.
Fantastic post Stonemasonn. Thank you for this little bit of...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.05 |
Change
-0.300(1.73%) |
Mkt cap ! $327.7M | |||
| Open | High | Low | Value | Volume |
| $17.00 | $17.44 | $16.95 | $184.6K | 10.84K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 191 | $17.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.50 | 500 | 1 |
View Market Depth
| Last trade - 15.59pm 19/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |